Bio


Chris Heitzig is a New Map of Life Postdoctoral Fellow in the Department of Epidemiology and Population Health. An economist by training, his research develops models to examine healthy aging across the life course, with a particular emphasis on identifying causal pathways and key points of policy intervention to improve well-being in later life. A central focus of his work is the socioeconomic impact of undiagnosed metabolic disorders—how these conditions manifest, the costs of leaving them untreated, and the potential for interventions to improve detection and outcomes. His research combines insights from economics and public health with machine learning methods for causal inference.

Before joining Stanford, Chris served in research roles at the Brookings Institution and the World Bank. At Brookings, he managed a $1.5 million research grant investigating how technological change is reshaping employment in Africa. At the World Bank, he designed randomized controlled trials to measure the causal effects of health and employment programs and served in an operational role as the day-to-day lead for a $20 million job transition program. Chris holds a PhD in Economics from the Institute of Development Studies, an MPhil in Economics from the University of Oxford, and a BA in Economics from Saint John’s University.

Stanford Advisors


All Publications


  • Diabetes and the Life-Course: Evidence from Panel Data and Electronic Health Records. medRxiv : the preprint server for health sciences Heitzig, C., Rehkopf, D. 2026

    Abstract

    Diabetes screening can alter both clinical care and patient behavior, but its consequences for health and socioeconomic outcomes remain uncertain. We examine these consequences in a fuzzy regression discontinuity design using electronic health records from the American Family Cohort (AFC) and longitudinal data from the Health and Retirement Survey (HRS). In AFC, we find that the diagnosis discontinuity peaks at 13 percentage points within six months and attenuates until it becomes insignificant at 42 months. We find a smaller and shorter-lived discontinuity for related prescriptions. These discontinuities remain across alternative specifications. Apart from specification and treatment window-dependent improvements in weight, BMI, and serum glucose, we do not observe a pattern of sustained improvement in cardiometabolic outcomes as a result of diagnosis and related care. In HRS, the threshold induces reductions of 22 percentage points in working for pay and 20.6 percentage points in labor-force participation at the two year follow-up. We do not observe a corresponding change in retirement, suggesting that diabetes diagnoses may lead to respondents reducing work without retirement. These reductions remain after several sensitivity checks but do not persist beyond two years. These findings suggest that health screening for chronic conditions may temporarily reduce labor supply, making employment responses relevant to the evaluation of broader costs and benefits of screening.

    View details for DOI 10.64898/2026.06.06.26355069

    View details for PubMedID 42996098

    View details for PubMedCentralID PMC13738907